Patients with HAE are likely struggling with disease and treatment burden1,2

Self-administration challenges, needle fatigue, and other issues may be weighing patients down1

In a study of 75 adults living with hereditary angioedema (HAE), approximately 90% of patients say they have learned to tolerate difficult aspects of their treatment, while 75% of patients say they try not to think about the demanding nature of their treatment.1

With the treatment landscape changing, you can talk with your patients about their satisfaction with their current therapy and what approach might best meet their needs.

Prophylactic therapy should be determined based on individual considerations2,3:

Disease-related factors
(physical, emotional, quality of life)

Treatment-related factors
(route of administration, side effects, availability/supply)

Patient preference
(lifestyle, dosing schedule, flexibility)

Shared decision making empowers patients to play a more active role in treatment decisions and be more compliant with their treatment, leading to better overall outcomes.4

Research shows there is a strong patient demand for an oral prophylactic therapy5

Data from a study of 75 patients with HAE demonstrate the preference for an oral preventative therapy.5

of the 48 patients on a prophylactic therapy would prefer an oral treatment if one were available even though they are satisfied with their current prophylactic therapy5

of the 48 patients on a prophylactic therapy agree that an oral prophylactic therapy would better fit their lives vs an injectable HAE medication5